FDA Press Office Shakeup Startles Ousted Staffers
This article was originally published in The Tan Sheet
Executive Summary
A young FDA official's decision to boot three seasoned press specialists from the Public Affairs Office may be an embarrassment for the agency.
You may also be interested in...
With Democrat In White House, “More Aggressive” FDA Comes Into Focus
Democratic control of the White House, Senate and House brings the potential of a "more aggressive" FDA into sharp focus
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.